Journal article · 2022

Case study: treatment-resistant schizophrenia

Pharmaceutical journal/The pharmaceutical journal · Published 1 January 2022 · DOI 10.1211/pj.2021.1.121281

View at the publisherCite this paper

In brief

“Case study: treatment-resistant schizophrenia” is a 2022 journal article, published in Pharmaceutical journal/The pharmaceutical journal. OpenAlex counts 0 citations as of 20 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0

Abstract

Background Around 0.5–0.7% of the UK population is living with schizophrenia. Of these individuals, up to one-third are classified as treatment-resistant. This is defined as schizophrenia that has not responded to two different antipsychotics​[1,2]​. Clozapine is the most effective treatment for such patients​[3]​. It is recommended by the National Institute for Health and Care Excellence… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Case study: treatment-resistant schizophrenia. (2022). Pharmaceutical journal/The pharmaceutical journal. https://doi.org/10.1211/pj.2021.1.121281

MLA 9

“Case study: treatment-resistant schizophrenia.” Pharmaceutical journal/The pharmaceutical journal, 2022. https://doi.org/10.1211/pj.2021.1.121281.

Chicago

2022. “Case study: treatment-resistant schizophrenia.” Pharmaceutical journal/The pharmaceutical journal. https://doi.org/10.1211/pj.2021.1.121281.

Harvard

(2022) ‘Case study: treatment-resistant schizophrenia’, Pharmaceutical journal/The pharmaceutical journal. doi:10.1211/pj.2021.1.121281.

IEEE

“Case study: treatment-resistant schizophrenia,” Pharmaceutical journal/The pharmaceutical journal, 2022, doi: 10.1211/pj.2021.1.121281.

BibTeX

@article{anon2022case,
  title     = {{Case study: treatment-resistant schizophrenia}},
  journal   = {Pharmaceutical journal/The pharmaceutical journal},
  year      = {2022},
  doi       = {10.1211/pj.2021.1.121281},
  url       = {https://doi.org/10.1211/pj.2021.1.121281}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • treatment-resistant schizophrenia
  • clozapine
  • antipsychotic drugs
  • antipsychotic non-response

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Case study: treatment-resistant schizophrenia. (2022). Pharmaceutical journal/The pharmaceutical journal. https://doi.org/10.1211/pj.2021.1.121281

How many times has this paper been cited?

0 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

What is the DOI of this paper?

10.1211/pj.2021.1.121281, permanently at https://doi.org/10.1211/pj.2021.1.121281. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.